When Riordan, Lewis & Haden Inc. (RLH), a private equity firm, found itself ensnared in a False Claims Act (FCA) litigation for its role in a prescription drug kickback scheme orchestrated by one of its portfolio companies,...more
12/11/2019
/ Best Practices ,
Board of Directors ,
Corporate Governance ,
Corporate Liability ,
Enforcement Actions ,
False Claims Act (FCA) ,
Health Care Providers ,
Kickbacks ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Portfolio Companies ,
Prescription Drugs ,
Private Equity Firms ,
Risk Management ,
Settlement ,
TRICARE